days of the effective date of the final Phase II rule.

(B) An interim progress report shall be submitted to EPA 6 months after the effective date of the final Phase II rule.

(5) *Mysid shrimp chronic toxicity testing*—(i) *Required testing.* Testing using measured concentrations, flow through or static renewal systems, and systems that control for evaporation of the test substance shall be conducted for 1,2,4-trichlorobenzene. Testing shall be conducted with mysid shrimp (*Mysidopsis bahia*) to develop data on the chronic toxicity of 1,2,3-trichlorobenzene, should the acute LC50 of this chemical to mysid shrimp be determined to be less than 1 ppm.

(ii) *Test standards.* The mysid shrimp (*Mysidopis bahia*) chronic toxicity test shall be conducted for 1,2,4-trichlorobenzene in accordance with §797.1950 of this chapter. Testing shall also be conducted according to §797.1950 for 1,2,3-trichlorobenzene should the results of testing required by (d)(1)(ii) of this section yield an acute LC50 for this chemical substance of less than 1 ppm.

(iii) *Reporting requirements.* (A) The mysid shrimp chronic toxicity test for 1,2,4-trichlorobenzene shall be completed and the final report submitted to EPA within 1 year of the effective date of the final Phase II rule. The mysid shrimp chronic toxicity test for 1,2,3-trichlorobenzene, (required if the LC50 is less than 1 ppm), shall be completed and final report submitted to EPA within 15 months of the effective date of the final Phase II rule.

(B) Progress reports shall be submitted to EPA at 6-month intervals, beginning 6 months after of the effective date of the final Phase II rule and until the final report is submitted to EPA.

(e) *Health effects testing*—(1) *Oncogenicity*—(i) *Required testing.* (A) A test for oncogenic effects shall be conducted with 1,2,4-TCB in accordance with §798.3300 of this chapter.

(B) The route of administration for the oncogenicity testing for 1,2,4-TCB shall be via the animal feed.

(C) Two rodent species shall be used and one shall be the Fischer-344 rat.

(ii) *Reporting requirements.* (A) The oncogenicity test shall be completed and the final results submitted to EPA by June 30, 1994.

(B) Progress reports shall be submitted to the Agency every 6 months after the effective date of the final rule.

(2) [Reserved]

(f) [Reserved]

(g) *Effective date.* (1) The effective date of the final phase II rule is August 14, 1987, except for paragraphs (d)(4)(iii)(A) and (e)(1)(ii)(A) of this section. The effective date for paragraph (d)(4)(iii)(A) of this section is March 1, 1990. The effective date for paragraph (e)(1)(ii)(A) of this section is June 12, 1992.

(2) The guidelines and other test methods cited in this rule are referenced as they exist on the effective date of the final rule.

[51 FR 11737, Apr. 7, 1986; 51 FR 18444, May 20, 1986, as amended at 51 FR 24667, July 8, 1986; 52 FR 24465, July 1, 1987; 55 FR 7327, Mar. 1, 1990; 57 FR 24960, June 12, 1992; 57 FR 27845, June 22, 1992; 58 FR 34205, June 23, 1993]

§799.1054 1,2,4,5-Tetrachlorobenzene.

(a) *Identification of test substances.* (1) 1,2,4,5-Tetrachlorobenzene (CAS Number 95–94–3) (hereinafter "1,2,4,5-TCB") shall be tested in accordance with this section.

(2) 1,2,4,5-TCB of at least 97 percent purity shall be used as the test substance.

(3) The test substance shall not contain more than 0.05 percent benzene and 0.05 percent hexachlorobenzene.

(b) *Persons required to submit study plans, conduct tests and submit data.* All persons who manufacture (import) or process 1,2,4,5-tetrachlorobenzene, other than as an impurity, after the effective date of this rule (August 21, 1986) to the end of the reimbursement period shall submit letters of intent to conduct testing or exemption applications, submit study plans, conduct tests, and submit data as specified in this section, subpart A of this part, and parts 790 and 792 of this chapter for single-phase rulemaking.

(c) *Health effects testing*—(1) *Reproduction and fertility*—(i) *Required testing.* (A) A test for reproduction and fertility effect shall be conducted with 1,2,4,5-TCB in accordance with §798.4700 of this chapter.

(B) The route of administration for the reproduction and fertility testing for 1,2,4,5-TCB shall be dietary.

(C) A rodent test species shall be used and shall be the Sprague-Dawley rat.

(ii) *Reporting requirements.* (A) The reproduction and fertility test shall be completed and the final results submitted to EPA within 32 months of the effective date of this final rule.

(B) Progress reports shall be submitted to the Agency every 6 months after the effective date of the final rule.

(2) *Developmental toxicity*—(i) *Required testing.* (A) A test of developmental toxicity shall be conducted with 1,2,4,5-TCB in accordance with § 798.4900 of this chapter.

(B) The route of administration for the developmental toxicity testing for 1,2,4,5-TCB shall be via oral gavage.

(C) Two rodent species shall be used in the study. One shall be the Fischer-344 rat and the second the New Zealand white rabbit.

(ii) *Reporting requirements.* (A) The developmental toxicity testing shall be completed and the final results submitted to the Agency within 16 months of the effective date of the test rule.

(B) Progress reports shall be submitted to the Agency every 6 months after the effective date of the final rule.

[51 FR 24667, July 8, 1986, as amended at 52 FR 10378, Apr. 1, 1987; 52 FR 26477, July 15, 1987; 54 FR 27355, June 29, 1989; 58 FR 34205, June 23, 1993]

§ 799.1250 Cresols.

(a) *Identification of test substances.* (1) *ortho*-Cresol (CAS No. 95-48-7), *meta*-cresol (CAS No. 108-39-4), and *para*-cresol (CAS No. 106-44-5) shall each be tested in accordance with this section.

(2) *ortho-, meta-,* and *para*-Cresol of at least 99 percent purity shall be used as the test substance.

(b) *Persons required to submit study plans, conduct tests, and submit data.* (1) All persons who manufacture or process or intend to manufacture or process cresols from the effective date of this rule (June 11, 1986) to the end of the reimbursement period shall submit letters of intent to conduct testing or exemption applications, study plans, and/or shall conduct tests and submit data as specified in this section, subpart A of this part, and part 790 of this chapter.

(2) Persons subject to this section are not subject to the requirements of §§ 790.50(a)(2), (5), and (6) and (b), and 790.87(a)(1)(ii) of this chapter.

(3) Persons who notify EPA of their intent to conduct tests in compliance with the requirements of this section must submit study plans for those tests no later than 30 days before the initiation of each of those tests.

(4) In addition to the requirements of § 790.87(a)(2) and (3) of this chapter, EPA will conditionally approve exemption applications for this rule if EPA has received a letter of intent to conduct the testing from which exemption is sought and EPA has adopted test standards and schedules in a final Phase II test rule.

(c) *Health effects testing*—(1) *Mutagenic effects—chromosomal aberrations*—(i) *Required testing.* (A) *In vitro* cytogenetics tests shall be conducted individually with *ortho-, meta-,* and *para*-cresol;

(B) An *in vivo* cytogenetics test shall be conducted for each isomer which produces a negative result in the *in vitro* cytogenetics test conducted pursuant to paragraph (c)(1)(i)(A) of this section.

(C) A dominant lethal assay shall be conducted for each isomer which produces a positive result in either the *in vitro* or the *in vivo* cytogenetics test conducted pursuant to paragraphs (c)(1)(i)(A) and (B) of this section.

(ii) *Test standards.* (A)(*1*) *In vitro mammalian cytogenetics test.* This test shall be conducted individually with *ortho-, meta-,* and *para*-cresols in accordance with § 798.5375 of this chapter, except for the provisions in paragraphs (d)(3)(i) and (4) and (6) (i) and (ii).

(*2*) For the purposes of this section the following provisions also apply:

(*i*) *Type of cells used in the assay. Ortho-, meta-,* and *para*-cresols shall be tested in established cell lines. The cell lines or strain shall be checked for *Mycoplasma* contamination.

(*ii*) *Metabolic activation.* The metabolic activation system for this assay shall be derived from Aroclor-1254 induced rat liver S-9 preparations.

(*iii*) *Test substance—Vehicle. Ortho-, meta-,* and *para*-cresols shall be dis-